Data investigation

FDA Warning Letters to Compounded GLP-1 Telehealth Providers: The Live Investigation

Every FDA warning letter we have identified that targets a compounded GLP-1 telehealth provider, compounding pharmacy, or related weight-loss business — with violation patterns, issuing offices, and what is actually being cited. Live dataset, updated bi-weekly via automated FDA scraper.

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed
10 min read·120 citations

Weight Loss Rankings maintains a continuously-updated database of every FDA warning letter we've been able to identify that targets a compounded GLP-1 telehealth provider, compounding pharmacy, or related weight-loss business. As of March 31, 2026, the database contains 120 letters spanning from October 2, 2023 to March 31, 2026. This investigation breaks down what FDA is actually citing — the violation categories, issuing offices, and the patterns that should make a prospective patient cautious about specific business models.

What FDA is citing, by subject category

Every letter in our database carries a verbatim subject line from the FDA letter itself. Grouping by subject reveals what the agency is actually concerned about right now.

Subject categoryLettersShare
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet4941%
False & Misleading Claims/Misbranded3428%
Compounded GLP-1 marketing and labeling concerns1714%
Compounding Pharmacy/Adulterated Drug Products65%
Unapproved New Drugs/Misbranded54%
Unapproved New Drugs Sold Over the Internet43%
CGMP/Finished Pharmaceuticals/Adulterated22%
Postmarketing Adverse Drug Experience Reporting Requirements11%
Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet11%
Finished Pharmaceutical/Unapproved New Drug/Adulterated/Misbranded11%

The dominant pattern is clear: 115 of 120 letters in the database (96%) target marketing, labeling, or compounding-quality issues at compounded GLP-1 telehealth businesses. Only 5 letters in the dataset address other concerns.

Magnitude comparison

FDA warning letter count by enforcement archetype across all 120 GLP-1-relevant letters in the WLR database. Buckets are derived from the verbatim FDA subject line on each letter. Source: FDA public warning letter index, retrieved through March 31, 2026.[1][2]

  • Online sellers (unapproved/misbranded drugs over the internet)59 letters
    peptide vendors + non-503A websites — Sept 9, 2025 multi-recipient sweep drove most of this bucket
  • Med spas & telehealth marketing (False & Misleading Claims)34 letters
    Feb 20, 2026 multi-recipient sweep drove most of this bucket
  • Compounded GLP-1 marketing & labeling concerns17 letters
    compounded pharmacies citing salt-form sourcing and FDA-approval misrepresentation
  • Compounding pharmacy adulteration (cGMP/inspection)7 letters
    the most serious bucket — sterility failures, environmental monitoring lapses
  • International suppliers (foreign cGMP findings)2 letters
    API-stage findings against overseas finished-product manufacturers
FDA warning letter count by enforcement archetype across all 120 GLP-1-relevant letters in the WLR database. Buckets are derived from the verbatim FDA subject line on each letter. Source: FDA public warning letter index, retrieved through March 31, 2026.

Issuing offices

Where the letter comes from inside FDA matters. Letters from the Center for Drug Evaluation and Research (CDER) are typically the result of an internet sweep — FDA staff find a website making questionable claims, and the violation letter follows. Letters from district field offices usually follow an in-person inspection of a compounding pharmacy.

Issuing officeLetters
Center for Drug Evaluation and Research (CDER)118
Center for Drug Evaluation and Research | CDER2

Every letter in our database

Each entry below links to our editorial summary plus a verbatim excerpt of what FDA cited. We add new letters within two weeks of FDA publication via an automated discovery and review process.

The patterns that should make you cautious

Reading every letter in the database reveals three recurring red flags worth knowing about as a patient:

  1. Branded compounded products. Several letters cite telehealth providers for putting their own brand name on the vial label of a compounded drug, suggesting to consumers that the compounded product was manufactured by the telehealth company itself. FDA considers this misbranding because the actual compounder is a third-party 503A pharmacy that the patient never sees.
  2. Implied FDA approval. Multiple letters cite marketing language that uses words like “safe,” “FDA-approved,” or “FDA-registered” in contexts that misrepresent the regulatory status of compounded drugs. Compounded semaglutide is not FDA-approved, no matter how the website phrases it.
  3. Adulteration findings on inspection. The letters from district field offices (rather than CDER) typically follow an in-person inspection that found cGMP violations — sterility failures, environmental monitoring lapses, or use of bulk drug substances that aren't eligible under the 503A or 503B exemptions. These are the most serious letters in the database.

How to use this database as a patient

Before you start a compounded GLP-1 program, search this database for the telehealth provider you're considering AND the compounding pharmacy they list as their fulfillment partner. A warning letter doesn't automatically mean the company is unsafe — many companies remediate the cited violations and continue operating — but it tells you what to ask about during your consultation.

Specific questions to ask any compounded GLP-1 provider:

  • Has your company or your fulfillment pharmacy received any FDA warning letters? If yes, what was cited and what changed?
  • Is your pharmacy registered with FDA as a 503B outsourcing facility? If not, which state board of pharmacy licenses them?
  • What is the exact form of semaglutide or tirzepatide in your product — base molecule, sodium salt, or acetate salt? FDA has warned that salt forms are not the same active ingredient as the base molecule used in approved drugs.

Methodology

Our FDA letter database is updated bi-weekly via an automated scraper that pulls from FDA's public warning letters index. Every letter we add is verified against the original FDA publication URL, with violation summaries quoted verbatim from the FDA letter text. We never paraphrase a violation. The full methodology is documented in our editorial standards.

Our pricing index, pharmacy database, and the rest of the WLR editorial dataset is documented at our master sources page. The underlying FDA letter records are in our public repository.

Related research

For the regulatory and market context this enforcement database fits into:

Are diet pills from Mexico safe?

No. The FDA does not regulate cross-border pharmaceutical imports, and the FDA Tainted Weight Loss Products database documents recurrent contamination of Mexico-sourced weight-loss pills with sibutramine (FDA-withdrawn 2010 for cardiovascular events) and fenfluramine derivatives (FDA-banned 1997 after Connolly et al. NEJM 1997 PMID 9271479 documented valvular heart disease in 24 fen-phen patients).

The most-discussed Mexican diet pill, Redotex, combines T3 thyroid hormone, atropine, aloin, diazepam (DEA Schedule IV), and historically fenfluramine derivatives. It is NOT FDA-approved and has been seized at US ports of entry. For the full polypill component breakdown, the FDA Tainted Weight Loss Products methodology, and the federal-law importation framework (FD&C Act §801 / 21 U.S.C. §381), see our full evidence review at Mexican diet pills: what's actually in them. The cheap, FDA-overseen alternatives in 2026 are Foundayo at $149/month via LillyDirect, Wegovy oral pill at $149/month via NovoCare through August 2026, and generic phentermine at $9–30/month at retail pharmacies.

References

  1. 1.U.S. Food and Drug Administration. Warning Letters — public index of all FDA enforcement letters (filtered for GLP-1 / compounded semaglutide / tirzepatide). FDA.gov. 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
  2. 2.U.S. Food and Drug Administration. FDA, FTC issue joint letters to telehealth platforms and online retailers selling unapproved versions of GLP-1 weight-loss drugs. FDA News Release (issuance of the September 9, 2025 multi-recipient enforcement sweep). 2025. https://www.fda.gov/news-events/press-announcements/fda-ftc-issue-joint-letters-telehealth-platforms-online-retailers-selling-unapproved-versions-glp-1